IP Verse

Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)

Patent No. EP3570885 (titled "Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)") was filed by Amgen on Jan 16, 2018. The application was issued on Sep 18, 2024.

Patent Summary

A composition for treating metabolic disorders, comprising a GLP-1 receptor agonist conjugated to an antigen binding protein that specifically binds to the gastric inhibitory peptide receptor (GIPR). The conjugate is used to treat conditions such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease by inhibiting GIPR activity.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JG OPPOSITIONSJun 18, 2025MATHYS & SQUIRE
CAMULONJun 17, 2025REDDIE & GROSE
BOULT WADE TENNANTJun 16, 2025BOULT WADE TENNANT

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3570885

AMGEN
Application Number
EP18714635A
Filing Date
Jan 16, 2018
Status
Granted And Under Opposition
Aug 15, 2024
Publication Date
Sep 18, 2024
External Links
Slate, Register , Google Patents